PHARMACEUTICAL COMPOSITION BASED ON PLGA FOR THE INDUCTION OF THE EFFECTIVE MUCOSAL IMMUNE RESPONSE Russian patent published in 2021 - IPC A61K38/00 A61K31/74 B82Y99/00 

FIELD: medical industry.

SUBSTANCE: pharmaceutical composition based on PLGA for the induction of mucosal immune response to prevent infections caused by bacterial and viral pathogens, consisting of antigen, packed inside PLGA polymer particles, the shell of which consists of a polymer of lactic-co-glycolic acids, where the composition further comprises a combination of agonists encapsulated inside PLGA particles, and particle size is less than 180 nm. The use of the above pharmaceutical composition for the induction of a mucosal immune response in the respiratory tract and in the gastrointestinal tract due to implementation of certain immunization regimens.

EFFECT: above pharmaceutical composition has high ability to induce a mucosal immune response and, depending on the application, namely, on the injection scheme, is able to cause this type of immune response in a focused manner in the respiratory or intestinal tract, where a multiple increase of the IgA titer is carried out.

6 cl, 1 tbl, 9 ex, 14 dwg